{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:22:20Z","timestamp":1792120940815,"version":"4.4.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at age 6 years compared with those treated with episodic FVIII for bleeding. The Joint Outcome Continuation Study (JOS-C) evaluated early vs delayed prophylaxis effects on long-term joint health, following JOS participants to age 18 years in an observational, partially retrospective study. Index joint magnetic resonance imaging (MRI) scores of osteochondral (OC) damage (primary outcome), joint physical examination scores, and annualized rates of joint\/other bleeding episodes (secondary outcomes) were collected. Thirty-seven of 65 JOS participants enrolled in JOS-C, including 15 randomized to prophylaxis at mean age 1.3 years (\u201cearly prophylaxis\u201d); 18 initially randomized to episodic treatment, starting \u201cdelayed prophylaxis\u201d at mean age 7.5 years; and 4 with high-titer inhibitors. At JOS-C exit, MRI OC damage was found in 77% of those on delayed and 35% of those on early prophylaxis for an odds ratio of OC damage, in the delayed vs early prophylaxis group, of 6.3 (95% confidence interval, 1.3, 29.9; P = .02). Annualized bleeding rates were higher with delayed prophylaxis (mean plus or minus standard deviation, 10.6 \u00b1 6.6 vs 3.5 \u00b1 2.1; P &amp;lt; .001), including when only comparing time periods on prophylaxis (6.2 \u00b1 5.3 vs 3.3 \u00b1 1.9; P &amp;lt; .05). In severe HA, early initiation of prophylaxis provided continued protection against joint damage throughout childhood compared with delayed initiation, but early prophylaxis was not sufficient to fully prevent damage. This trial was registered at www.clinicaltrials.gov as #NCT01000844.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001311","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T12:59:10Z","timestamp":1591189150000},"page":"2451-2459","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4416-3031","authenticated-orcid":false,"given":"Beth Boulden","family":"Warren","sequence":"first","affiliation":[{"name":"Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO;"},{"name":"Center for Cancer and Blood Disorders, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-4166","authenticated-orcid":false,"given":"Dianne","family":"Thornhill","sequence":"first","affiliation":[{"name":"Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0289-4805","authenticated-orcid":false,"given":"Jill","family":"Stein","sequence":"first","affiliation":[{"name":"Section of Pediatric Radiology, Children\u2019s Hospital Colorado, Aurora, CO;"},{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fadell","sequence":"first","affiliation":[{"name":"Section of Pediatric Radiology, Children\u2019s Hospital Colorado, Aurora, CO;"},{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Ingram","sequence":"first","affiliation":[{"name":"Section of Pediatric Radiology, Children\u2019s Hospital Colorado, Aurora, CO;"},{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-6140","authenticated-orcid":false,"given":"Sharon","family":"Funk","sequence":"first","affiliation":[{"name":"Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi L.","family":"Norton","sequence":"first","affiliation":[{"name":"Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi D.","family":"Lane","sequence":"first","affiliation":[{"name":"Primary Children\u2019s Hospital, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Bennett","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA;"},{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Children\u2019s Healthcare of Atlanta, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-6365","authenticated-orcid":false,"given":"Amy","family":"Dunn","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA;"},{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Children\u2019s Healthcare of Atlanta, Atlanta, GA;"},{"name":"Nationwide Children\u2019s Hospital, Columbus, OH;"},{"name":"Division of Hematology, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-1016","authenticated-orcid":false,"given":"Michael","family":"Recht","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-7159","authenticated-orcid":false,"given":"Amy","family":"Shapiro","sequence":"first","affiliation":[{"name":"Indiana Hemophilia and Thrombosis Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-1482","authenticated-orcid":false,"given":"Marilyn J.","family":"Manco-Johnson","sequence":"first","affiliation":[{"name":"Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO;"},{"name":"Center for Cancer and Blood Disorders, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"4","key":"2020060311310350300_B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2516.2007.01473.x","article-title":"Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS","volume":"13","author":"Su","year":"2007","journal-title":"Haemophilia"},{"key":"2020060311310350300_B2","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2147\/PPA.S141392","article-title":"Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study","volume":"11","author":"Buckner","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2020060311310350300_B3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"2020060311310350300_B4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2020060311310350300_B5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients\u2013a long-term follow-up","volume":"241","author":"L\u00f6fqvist","year":"1997","journal-title":"J Intern Med"},{"issue":"4","key":"2020060311310350300_B6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"2020060311310350300_B7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0022-3476(98)70382-8","article-title":"Prophylaxis for hemophilia: state of the art or state of confusion?","volume":"132","author":"Gruppo","year":"1998","journal-title":"J Pediatr"},{"issue":"11","key":"2020060311310350300_B8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco-Johnson","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2020060311310350300_B9","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V99.7.2337","article-title":"The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia","volume":"99","author":"Fischer","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2020060311310350300_B10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/hae.12108","article-title":"Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia","volume":"19","author":"Bladen","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"2020060311310350300_B11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"9","key":"2020060311310350300_B12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2020060311310350300_B13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2020060311310350300_B14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-09-743385","article-title":"Novel therapeutics for hemophilia and other bleeding disorders","volume":"132","author":"Callaghan","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020060311310350300_B15","doi-asserted-by":"crossref","first-page":"Abstract 636","DOI":"10.1182\/blood-2018-99-113575","article-title":"BIVV001: the first investigational factor VIII therapy to break through the VWF ceiling in hemophilia A, with potential for extended protection for one week or longer [abstract]","volume":"132","author":"Konkle","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020060311310350300_B16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26865","article-title":"Gene therapy for hemophilia","volume":"65","author":"Pipe","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2020060311310350300_B17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2516.2006.01292.x","article-title":"The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia","volume":"12","author":"Pollak","year":"2006","journal-title":"Haemophilia"},{"issue":"6","key":"2020060311310350300_B18","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1111\/hae.13022","article-title":"SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data","volume":"22","author":"Hong","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"2020060311310350300_B19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1365-2516.2000.00383.x","article-title":"MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage","volume":"6","author":"Nuss","year":"2000","journal-title":"Haemophilia"},{"issue":"1","key":"2020060311310350300_B20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2516.2006.01387.x","article-title":"The Colorado Haemophilia Paediatric Joint Physical Examination Scale: normal values and interrater reliability","volume":"13","author":"Hacker","year":"2007","journal-title":"Haemophilia"},{"key":"2020060311310350300_B21","volume-title":"The Haemophilic Joints: New Perspectives","author":"Manco-Johnson","year":"2003"},{"issue":"11","key":"2020060311310350300_B22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2020060311310350300_B23","volume-title":"Playing it Safe; Bleeding Disorders, Sports and Exercise","author":"Anderson","year":"2005"},{"key":"2020060311310350300_B24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","article-title":"Repeated measures correlation [published correction appears in Front Psychol. 2019;10:1201]","volume":"8","author":"Bakdash","year":"2017","journal-title":"Front Psychol"},{"key":"2020060311310350300_B25","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511761676","volume-title":"The Essential Guide to Effect Sizes: Statistical Power, Meta-Analysis, and the Interpretation of Research Results","author":"Ellis","year":"2010"},{"issue":"1","key":"2020060311310350300_B26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"issue":"1","key":"2020060311310350300_B27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0031-1300954","article-title":"Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2020060311310350300_B28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"2020060311310350300_B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bcmd.2017.02.004","article-title":"Primary prophylaxis in haemophilia care: guideline update 2016","volume":"67","author":"Fischer","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2020060311310350300_B30","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2020060311310350300_B31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/hae.12959","article-title":"Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia","volume":"22","author":"Nijdam","year":"2016","journal-title":"Haemophilia"},{"issue":"s","key":"2020060311310350300_B32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2516.2004.00978.x","article-title":"Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions","volume":"10","author":"Manco-Johnson","year":"2004","journal-title":"Haemophilia"},{"issue":"14","key":"2020060311310350300_B33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2012.12727","article-title":"Association between physical activity and risk of bleeding in children with hemophilia","volume":"308","author":"Broderick","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"2020060311310350300_B34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/jth.14651","article-title":"Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate-severe hemophilia A","volume":"18","author":"Funk","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020060311310350300_B35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/acr.20353","article-title":"Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score","volume":"63","author":"Feldman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"22","key":"2020060311310350300_B36","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2451\/1743444\/advancesadv2019001311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2451\/1743444\/advancesadv2019001311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T12:59:37Z","timestamp":1591189177000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/11\/2451\/460607\/Young-adult-outcomes-of-childhood-prophylaxis-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001311","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]}}}